Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 348

Protein Synthesis

Posted by fidest press agency su martedì, 19 Maggio 2009

New York, Promosome LLC, a biotechnology company specializing in technologies related to the regulation of protein synthesis through translation initiation, today announced the signing of a non-exclusive technology evaluation contract with Lonza Biologics. Lonza is a recognized leader providing a large repertoire of contract manufacturing and enabling technologies to the pharmaceutical and biopharmaceutical industry. Under the terms of the agreement, Lonza will evaluate Promosome’s Translation Enhancing Elements (TEEs) in combination with its proprietary GS(tm) expression technology. Promosome’s TEEs are synthetic messenger RNA (mRNA) sequences that can be used to greatly enhance protein expression in a variety of eukaryotic cells. TEEs are expected to be highly complementary to Lonza’s proprietary GS(tm) expression technology.
Promosome is a New York City based biotechnology company founded by the highly regarded Life Sciences commercialization team of William J. Gedale and John R. Costantino. The mission of Promosome is to leverage and commercialize the discoveries of Nobel Laureate Dr. Gerald M. Edelman, Dr. Vincent P. Mauro and their colleagues at The Scripps Research Institute (TSRI) in La Jolla, California while in parallel, offering a significant return to investors and contributing to the advancement of the biotechnology industry. Promosome has established a Research Funding and Option Agreement with TSRI and the laboratories of Doctors Edelman and Mauro. Promosome has world-wide exclusive license and sub-license rights to the TEE Technology.
Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strongcapabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2007, Lonza had sales of CHF 2.87 billion.


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di

Stai commentando usando il tuo account Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

%d blogger hanno fatto clic su Mi Piace per questo: